Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy

Documenti analoghi

• Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor
  di: Guiming Deng, et al.
  Pubblicazione: (2024)
• Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
  di: Yuan Meng, et al.
  Pubblicazione: (2024)
• Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
  di: Shuling Shi, et al.
  Pubblicazione: (2024)
• Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma
  di: Angela E. Alnemri, et al.
  Pubblicazione: (2024)
• Early identification of severe immune checkpoint inhibitor associated myocarditis: From an electrocardiographic perspective
  di: Yongyin Gao, et al.
  Pubblicazione: (2024)